<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="371411">
  <stage>Registered</stage>
  <submitdate>30/08/2016</submitdate>
  <approvaldate>12/09/2016</approvaldate>
  <actrnumber>ACTRN12616001277437</actrnumber>
  <trial_identification>
    <studytitle>Comparison of two drug thinning agents (unfractionated heparin and low-molecular weight heparin) for prevention of stroke after brain aneurysm treatment utilizing coils or stents</studytitle>
    <scientifictitle>Enoxaparin for Postoperative Prophylaxis in Intracranial Coiling and Stents (EPPICS): A randomized trial of low molecular weight heparin and unfractionated heparin for prevention of arterial thromboembolic complications after endovascular intracranial aneurysm treatment </scientifictitle>
    <utrn>U1111-1187-0444</utrn>
    <trialacronym>EPPICS</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Intracranial Aneurysm</healthcondition>
    <healthcondition>Intracranial Lesions</healthcondition>
    <conditioncode>
      <conditioncode1>Stroke</conditioncode1>
      <conditioncode2>Ischaemic</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Stroke</conditioncode1>
      <conditioncode2>Ischaemic</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Endovascular treatment of intracranial aneurysm with coils and stents requires procedural anticoagulation, most commonly with unfractionated intravenous heparin (UFH). Where the risk of thromboembolic complications is high (eg post stenting) heparinisation is continued for 24-48hrs post treatment. Post-procedural anticoagulation regimes aim for therapeutic range based on repeated laboratory testing of sampled blood. In practice this can be difficult to achieve with consistency using UFH. Low molecular weight heparin (LMWH) offers some theoretical advantages over UFH but there is no published data on its use in neurointervention.

We propose to compare post-procedural anticoagulation using UFH with LMWH (enoxaparin) in patients treated electively for intracranial aneurysms. Patients who meet entry criteria will be randomised to one of three regimes: 
a) UFH - continuous IV infusion, titrated by APTT test results (current standard of care)
b) LMWH given as a single dose of 1.5mg/kg by subcutaneous injection at the end of the procedure 
c) LMWH given 1.0mg/kg by subcutaneous injection at the end of the procedure and at 12hours.
</interventions>
    <comparator>Comparator group:
1) Unfractionated Heparin (UFH)

Comparisons will be made between the above and these additional groups of anticoagulants
2) Low-molecular weight heparin (single dose, 1.5mg/kg)
3) Low-molecular weight heparin (split dose, 1.0mh/kg, BD)</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary outcome will be achievement of therapeutic range as assessed by APTT (UFH) or anti Xa (LMWH) testing

Patients will be categorized in a binary fashion  either being within the therapeutic range or being sub/supratherapeutic. </outcome>
      <timepoint>Within 24-48h hours of administered medication</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary outcome 1: The frequency of thromboembolic complications (either symptomatic or asymptomatic) in post-operative intracranial aneurysm coiling, including stent or balloon assisted coiling within the first 24-48 hours after cessation of intraoperative heparin, as assessed by neurological examination and pre- / post- procedure MRI</outcome>
      <timepoint>Neurological Examination within 24 hours of conclusion of endovascular procedure
MRI brain scan within 48 hours after the conclusion of endovascular procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary Outcome 2: The frequency of hemorrhagic complications in post-operative intracranial aneurysm coiling, including stent or balloon assisted coiling within the first 24-48 hours after cessation of intraoperative heparin, as assessed by neurological examination and pre- / post- procedure MRI</outcome>
      <timepoint>Neurological Examination within 24 hours of conclusion of endovascular procedure
MRI brain scan within 48 hours after the conclusion of endovascular procedure</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients admitted for elective endovascular treatment of intracranial aneurysm are eligible for inclusion.
Participants should understand the project and provide voluntary consent

Eligible patients will be admitted to the study if at the end of the endovascular procedure the operator determines that a period of post procedural anticoagulation is clinically indicated. The 3 most common reasons for this are:
1) Placement of an indwelling endovascular device, such as a stent
2) Presence of procedural platelet aggregation
3) Perceived increased risk of thromboembolic events due to 
(3a) large area of coil exposure at aneurysm neck 
(3b) loop protrusion into parent artery
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>&lt; 18 years of age (i.e. paediatric population)
- acute endovascular treatment (eg acute subarachnoid haemorrhage)
- impaired renal function (eGFR &lt; 30)
- MRI contraindications (e.g. pacemakers)
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed Opaque envelopes (numbered):
Operator will select the top package from a stack, which they are unaware of the contents of.</concealment>
    <sequence>Simple randomisation using a randomisation table created by computer software</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>This will be done in conjunction with the QIMR Berghofer Statistics Unit.
The primary endpoint will be to compare the proportion of therapeutic anticoagulation across all three arms. We will further determine whether there are differences between arms with respect to symptomatic or asymptomatic arterial thromboembolic events in unruptured intracranial aneurysms and whether there are differences in the immediate post-operative period after intracranial endovascular aneurysm coiling and/or stenting with respect to reduction in cerebral microbleeds. We will test for balance between arms and tabulate the variables listed above using chi-squared tests for factor variables and appropriate tests of means, either parametric or nonparametric tests. The remainder of the analyses will be descriptive, which will motivate the design of a larger randomized trial

Results from 2016 suggest between 50-100 patients per year adhering to the criteria
The initial patient aim will be 75 patients, 25 per arm. This is partially a sample size of convenience, This study will have limited utility in detecting non-inferiority between the two experimental arms and unfractionated heparin with respect to the proportion of patients achieving therapeutic anticoagulation, but it is intended that the cohort will be expanded if this initial pilot study is successful. With N = 25 per arm and assuming a 25% non-inferiority bound around the difference between the proportion of patients on two equally-allocated treatment arms, achieving 90% therapeutic anticoagulation each, we will have 80% power to conclude non-inferiority at an alpha of 0.05. 
</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>20/09/2016</anticipatedstartdate>
    <actualstartdate>22/11/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>75</samplesize>
    <actualsamplesize />
    <currentsamplesize>32</currentsamplesize>
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Royal Brisbane &amp; Womens Hospital - Herston</hospital>
    <postcode>4029 - Herston</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Brisbane and Women's Hospital</primarysponsorname>
    <primarysponsoraddress>Butterfield Street
Herston, QLD
4029</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Royal Australian and New Zealand College of Radiologists</fundingname>
      <fundingaddress>Radiology Research Committee
The Royal Australian and New Zealand College of Radiologists
Level 9, 51 Druitt St
Sydney, NSW 2000
</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Professor Alan Coulthard</sponsorname>
      <sponsoraddress>L3 Ned Hanlon Building
Butterfield Street
Royal Brisbane and Women's Hospital
Herston, 4029
QLD
Australia</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Endovascular treatment of intracranial aneurysm with coils and stents requires procedural anticoagulation, most commonly with unfractionated intravenous heparin (UFH). Where the risk of thromboembolic complications is high (eg post stenting) heparinisation is continued for 24-48hrs post treatment. Post-procedural anticoagulation regimes aim for therapeutic range based on repeated laboratory testing of sampled blood. In practice this can be difficult to achieve with consistency using UFH. Low molecular weight heparin (LMWH) offers some theoretical advantages over UFH but there is no published data on its use in neurointervention.

We propose to compare post-procedural anticoagulation using UFH with LMWH (enoxaparin) in patients treated electively for intracranial aneurysms. Patients who meet entry criteria will be randomised to one of three regimes: 
a) UFH - continuous IV infusion, titrated by APTT test results (current standard of care)
b) LMWH given as a single dose of 1.5mg/kg by subcutaneous injection at the end of the procedure 
c) LMWH given 1.0mg/kg by subcutaneous injection at the end of the procedure and at 12hours.

The primary outcome will be achievement of therapeutic range as assessed by APTT (UFH) or anti Xa (LMWH) testing.
The secondary outcome will be development of a clinically evident thromboembolic event (CETE) or a clinically silent lesion, either ischaemic (CSIL) or hemorrhagic (CSHL), assessed by neurological examination at 24 hours and MRI at 48hrs.
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Brisbane &amp; Womenâ€™s Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Human Research Ethics Committee
Block 7, Floor 7
Butterfield Street
Royal Brisbane and Women's Hospital
Herston
QLD, 4029</ethicaddress>
      <ethicapprovaldate>1/08/2016</ethicapprovaldate>
      <hrec>HREC/16/QRBW/326</hrec>
      <ethicsubmitdate>1/07/2016</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Alan Coulthard</name>
      <address>L3 Ned Hanlon Building
Royal Brisbane and Women's Hospital
Butterfield Street
Herston, QLD
4029</address>
      <phone>+61 7 3646 8599</phone>
      <fax />
      <email>a.coulthard@uq.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jeffrey Hocking</name>
      <address>L3 Ned Hanlon Building
Royal Brisbane and Women's Hospital
Butterfield Street
Herston, QLD
4029</address>
      <phone>+61 7 3646 7225</phone>
      <fax />
      <email>dmi.research.rbwh@gmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jeffrey Hocking</name>
      <address>L3 Ned Hanlon Building
Royal Brisbane and Women's Hospital
Butterfield Street
Herston, QLD
4029</address>
      <phone>+61 7 3646 7225</phone>
      <fax />
      <email>dmi.research.rbwh@gmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jeffrey Hocking</name>
      <address>L3 Ned Hanlon Building
Royal Brisbane and Women's Hospital
Butterfield Street
Herston, QLD
4029</address>
      <phone>36467225</phone>
      <fax />
      <email>dmi.research.rbwh@gmail.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>